Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer

Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage... ORIGINAL ARTICLE Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer Frank C. Detterbeck, MD, FACS, FCCP,* Mark A. Socinski, MD,† Richard J. Gralla, MD,‡ Martin J. Edelman, MD,§ Thierry M. Jahan, MD, David M. Loesch, MD,¶ Steven A. Limentani, MD,# Ramaswamy Govindan, MD,** M. B. Zaman, MD,†† Zhishen Ye, PhD,‡‡ Matthew J. Monberg, MS,‡‡ and Coleman K. Obasaju, MD, PhD‡‡ survival for all patients was 45 months (65.5% censored), with Background: Surgical resection alone remains suboptimal for pa- 87.2% alive at 1 year and 69.8% alive at 2 years. tients with early-stage (I or II) non-small cell lung cancer. Two Discussion: Neoadjuvant chemotherapy with gemcitabine was fea- similar randomized phase II trials were conducted to define an active sible and well tolerated, and outcomes were similar to other reports preoperative regimen in this disease state. of this treatment strategy. However, no regimen achieved the pre- Methods: In the first study, patients were randomized to receive defined pCR rate that would be sufficient to warrant further evalu- 2 2 gemcitabine 1000 mg/m on days 1 and 8 plus cisplatin 80 mg/m on ation in the phase III setting. This trial design provides an efficient day http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer

Obasaju, Coleman K.
Journal of Thoracic Oncology , Volume 3 (1) – Jan 1, 2008
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/neoadjuvant-chemotherapy-with-gemcitabine-containing-regimens-in-rKRWGMn4kk

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31815e5d9a
pmid
18166839
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer Frank C. Detterbeck, MD, FACS, FCCP,* Mark A. Socinski, MD,† Richard J. Gralla, MD,‡ Martin J. Edelman, MD,§ Thierry M. Jahan, MD, David M. Loesch, MD,¶ Steven A. Limentani, MD,# Ramaswamy Govindan, MD,** M. B. Zaman, MD,†† Zhishen Ye, PhD,‡‡ Matthew J. Monberg, MS,‡‡ and Coleman K. Obasaju, MD, PhD‡‡ survival for all patients was 45 months (65.5% censored), with Background: Surgical resection alone remains suboptimal for pa- 87.2% alive at 1 year and 69.8% alive at 2 years. tients with early-stage (I or II) non-small cell lung cancer. Two Discussion: Neoadjuvant chemotherapy with gemcitabine was fea- similar randomized phase II trials were conducted to define an active sible and well tolerated, and outcomes were similar to other reports preoperative regimen in this disease state. of this treatment strategy. However, no regimen achieved the pre- Methods: In the first study, patients were randomized to receive defined pCR rate that would be sufficient to warrant further evalu- 2 2 gemcitabine 1000 mg/m on days 1 and 8 plus cisplatin 80 mg/m on ation in the phase III setting. This trial design provides an efficient day

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2008

References

  • Global cancer statistics, 2002
    Parkin
  • Current standards of care in small-cell and non-small-cell lung cancer
    Schiller
  • Cancer statistics, 2006
    Jemal
  • Screening, diagnosis, and staging of lung cancer
    Shepherd
  • Chemotherapy for advanced non-small-cell lung cancer
    Walling
  • Revisions in the international system for staging lung cancer
    Mountain
  • Regional lymph node classification for lung cancer staging
    Mountain
  • Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA
    van Rens
  • Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study
    Ahrendt
  • Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer–preliminary results of Cancer and Leukemia Group B Trial 9761
    D'Cunha
  • Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer
    Pantel
  • Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer
    Passlick
  • Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Arriagada
  • ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I–III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up (Abstract 7013)
    Douillard
  • Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial
    Rosell
  • Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer
    Scagliotti
  • Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 (Abstract 7007)
    Strauss
  • Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
    Betticher
  • Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging
    Trodella
  • Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer
    Depierre
  • Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team
    Pisters
  • Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer
    Takeda
  • Preclinical characteristics of gemcitabine
    Plunkett
  • Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study
    Gatzemeier
  • Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer
    Manegold